Original articlePancreas, biliary tract, and liver: EditorialSevere Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival
References (27)
- et al.
Hepatitis C virus kinetics during and immediately after liver transplantation
Hepatology
(2002) - et al.
Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
Hepatology
(1996) - et al.
Successful treatment of fibrosing cholestatic hepatitis after liver transplantation
Transplant Proc
(2011) - et al.
International Liver Transplantation Society Expert P. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C
Liver Transpl
(2003) - et al.
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite
Liver Transpl
(2003) - et al.
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C
Am J Transplant
(2013) - et al.
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late
Dig Liver Dis
(2014) - et al.
Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
Gastroenterology
(2015) - et al.
Virology and pathogenesis of hepatitis C virus recurrence
Liver Transpl
(2008) - et al.
Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation
Hepatol Res
(2011)
Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation
Transplantation
Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis
Liver Int
Liver transplantation in adults coinfected with HIV
Transplantation
Cited by (3)
How I treat hepatitis C virus infection in patients with hematologic malignancies
2016, BloodCitation Excerpt :In both the liver transplant and HCT settings, use of mycophenolate mofetil has been linked to development of fibrosing cholestatic hepatitis C; thus, this drug should probably not be used in HCV-infected patients.29,81 In the HCT setting, DAAs against HCV would likely reduce the burden of intracellular virus29 and reduce the mortality rate of fibrosing cholestatic hepatitis C, as has been observed with successful DAA therapy of fibrosing cholestatic hepatitis C in the liver transplant setting.82-84 In a parallel situation, the frequency of fibrosing cholestatic hepatitis B in HCT recipients has plummeted since the introduction of pre-emptive use of lamivudine or entecavir.85
Mechanisms of liver disease in patients infected with HIV
2017, BMJ Open Gastroenterology
Conflicts of interest This author discloses the following: Norah Terrault has received research support from Gilead, Genetech/Roche, Vertex, Novartis, Eisai, and AbbVie, and has served as a consultant for Bristol-Myers Squibb. None of these companies had any role in this study. The remaining author discloses no conflicts.
Funding Supported by scholarships from Hepatology and Gastroenterology Services, Centre Hospitalier de l'Université de Montréal and the Fondation du Centre Hospitalier de l'Université de Montréal (J.M.G.), and by the University of California San Francisco Liver Center (National Institutes of Health P30 DK 026743 to N.A.T.).